This is a StreetInsider.com Premium Only Page

Lannett (LCI) – PRNewswire

May 1, 2023 06:55 AM Lannett Company, Inc. Enters Into Restructuring Support Agreement

Apr 20, 2023 06:53 AM NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

Apr 4, 2023 06:55 AM LANNETT SHARES UPDATE

Feb 1, 2023 04:15 PM LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

Jan 25, 2023 04:30 PM LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT

Jan 25, 2023 06:52 AM LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

Jan 4, 2023 06:52 AM LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS

Nov 7, 2022 06:52 AM LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM

Nov 2, 2022 04:15 PM LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE

Oct 26, 2022 06:52 AM LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2

Oct 21, 2022 06:53 AM LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT

Oct 19, 2022 06:55 AM LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS

Aug 31, 2022 06:53 AM LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE

Aug 24, 2022 04:15 PM LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS

Aug 19, 2022 06:52 AM LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24

Jun 1, 2022 06:52 AM LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

May 12, 2022 06:52 AM LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP

May 4, 2022 04:15 PM LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS

Apr 27, 2022 06:52 AM LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4

Mar 29, 2022 06:52 AM LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

Mar 18, 2022 04:15 PM LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE

Mar 4, 2022 05:33 PM LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14

Mar 4, 2022 04:15 PM LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE

Mar 4, 2022 06:52 AM LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million

Feb 3, 2022 04:15 PM LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE

Jan 27, 2022 06:52 AM LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3

Jan 21, 2022 06:52 AM LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

Dec 20, 2021 06:52 AM LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

Nov 3, 2021 04:15 PM Lannett Reports Fiscal 2022 First-Quarter Financial Results; Revises Down Full-year Guidance

Oct 28, 2021 06:52 AM Lannett To Report Fiscal 2022 First-quarter Financial Results, Host Conference Call On Wednesday, November 3

Aug 30, 2021 06:52 AM Lannett Commences Marketing Mycophenolate Mofetil For Oral Suspension

Aug 25, 2021 04:15 PM Lannett Announces Fiscal 2021 Fourth-Quarter, Full-Year Financial Results

Aug 18, 2021 06:52 AM Lannett To Report Fiscal 2021 Fourth-quarter, Full-year Financial Results, Host Conference Call On Wednesday, August 25

Jul 29, 2021 06:52 AM LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

Jul 12, 2021 06:52 AM Lannett Launches Fluvastatin Sodium ER Tablets

Jun 1, 2021 06:52 AM Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing

May 27, 2021 05:47 PM Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Service Properties Trust to Join S&P SmallCap 600

May 5, 2021 04:15 PM Lannett Announces Fiscal 2021 Third-Quarter Financial Results

Apr 28, 2021 06:53 AM Lannett To Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 5

Apr 22, 2021 04:15 PM Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility

Apr 9, 2021 06:52 AM Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026

Apr 6, 2021 07:21 AM Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026

Apr 1, 2021 08:30 AM Lannett Submits ANDA For Generic ADVAIR DISKUS®

Mar 10, 2021 06:52 AM Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance

Feb 9, 2021 06:53 AM Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin

Feb 8, 2021 06:52 AM Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets

Feb 3, 2021 04:15 PM Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations

Jan 27, 2021 06:52 AM Lannett To Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 3

Dec 7, 2020 04:15 PM Lannett Announces New $30 Million Revolving Credit Facility

Nov 30, 2020 06:52 AM Lannett Pays Off, In Full, Remaining Term A Loans